Summary:
Pirarubicin, THP-ADM (Tetrahydropyranoyl-adriamycin) is a new analogue of Adria-mycin, the advantage of which consists in minimal cardiotoxicity. The antitumor effectivity, side effects and other properties of Pirarubicin were evaluated in phase I and II studies using at least 3 dosage schedules. The antitumor efficacy seems following up to date experience similar to Adriamycin. Pirarubicin is effective especially in breast cancer haematological malignancies, lung cancer and head & neck cancer. Favourable results have been achieved in intraarterial chemotherapy of head & neck cancer and hepatic tumors and intracavitary bladder cancer. The dose limiting side effect is definitely myelosupression. Cariotoxic side effects are rare, respecting the limit of cumulative dose, there is not any myocardial damage imminent. Other side effects are mild. The dosage schedules cannot be compared on the basis of refered results as well as the possibilities of Adriamycin replacement by Pirarubicin cannot be accurately assessed.
Pirarubicin (THP-Adriamycin)
